Daily FNArena News - Small Caps
All | Australia | Book Reviews | Commodities | ESG Focus | FYI | International | Small Caps | SMSFundamentals | Technicals | Treasure ChestPrevious Stories
Dr Boreham’s Crucible: Paradigm Biopharmaceuticals
Nov 06 2023
Tim Boreham highlights the success of Paradigm Biopharmaceuticals’ joint pain drug ahead of a capital raising
Dropsuite Trajectory Impresses
Oct 25 2023
Already enthusiastic analysts have lifted their enthusiasm regarding Dropsuite’s outlook following impressive third quarter results
Dr Boreham’s Crucible: Cyclopharm
Oct 09 2023
FDA approval for Cyclopharm’s device-as-a-drug is welcome news, Tim Boreham reports
ASX Seafood Sector Swimming Against The Tide
Oct 05 2023
The New Criterion’s Tim Boreham navigates the choppy seas of a fraught Australian seafood-farming market
Sigma Healthcare Promises Higher Margins
Oct 03 2023
While interim results for Sigma Healthcare met expectations, brokers see margin upside from improved operating leverage
Dr Boreham’s Crucible: Argenica Therapeutics
Sep 28 2023
Argenica Therapeutics is aiming for a substantial slice of the stroke market, expected to be worth some US$180bn a year by 2030
Lindsay Australia: Transported To Growth
Sep 13 2023
Brokers are excited about the growth prospects of rural transport and logistics company Lindsay Australia as it becomes the number one player in its industry
Dr Boreham’s Crucible: Painchek
Sep 11 2023
Tim Boreham highlights a device used to detect pain in non-verbal patients, such as those suffering dementia and infants
Dr Boreham’s Crucible: Cleo Diagnostics
Aug 30 2023
Tim Boreham shines a light on freshly listed Cleo Diagnostics, in search of an effective diagnostic tool for ovarian cancer
Paw Patrol; Investing In Non-Discretionary Pets
Aug 28 2023
Let’s talk about the unbreakable bond between households and their pets, and about the companies that offer exposure. Updated with today’s FY23 result release
